Los resultados financieros trimestrales no suelen ser demasiado relevantes para el valor en este tipo de compañías que investigan, aún no venden nada y por tanto están en pérdidas, pero nunca se sabe.
Sobre posibles novedades, me acaba de llegar esta nota de prensa:
Threshold Pharmaceuticals Announces Presentation and Webcast at BioCentury Future Leaders Conference
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/13/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Chief Executive Officer of Threshold, is scheduled to present at the 19th Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, April 20, at 10:30 a.m. Eastern time in New York City.
A live webcast of the presentation will be available under Webcasts in the Investors section of www.thresholdpharm.com. A replay of the presentation will be archived on the site for 90 days
(http://investor.thresholdpharm.com/releasedetail.cfm?ReleaseID=663934)
No es el foro donde yo esperaría novedades sobre los ensayos, pero... ¡ah! y el CEO sí se sabe explicar, no como el sieso de la AACR
S2